FAXDC2

Summary

FAXDC2 (fatty acid hydroxylase domain containing 2, HGNC:1334) is a protein-coding gene on chromosome 5q33.2, encoding Fatty acid hydroxylase domain-containing protein 2 (Q96IV6). Promotes megakaryocyte differentiation by enhancing ERK phosphorylation and up-regulating RUNX1 expression.

Predicted to enable C-4 methylsterol oxidase activity. Involved in positive regulation of megakaryocyte differentiation and positive regulation of protein phosphorylation. Located in cytoplasm.

Source: NCBI Gene 10826 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 52 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_032385

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1334
Approved symbol	FAXDC2
Name	fatty acid hydroxylase domain containing 2
Location	5q33.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13758
Ensembl gene	ENSG00000170271
Ensembl biotype	protein_coding
OMIM	619853
Entrez	10826

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 12 protein_coding, 5 retained_intron, 4 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000326080, ENST00000423554, ENST00000517448, ENST00000517874, ENST00000517938, ENST00000518651, ENST00000519258, ENST00000519501, ENST00000520461, ENST00000520581, ENST00000520968, ENST00000521518, ENST00000522825, ENST00000523997, ENST00000524250, ENST00000524363, ENST00000888401, ENST00000888402, ENST00000888403, ENST00000888404, ENST00000888405, ENST00000962790

RefSeq mRNA: 1 — MANE Select: NM_032385 NM_032385

CCDS: CCDS43390

Canonical transcript exons

ENST00000326080 — 9 exons

Exon	Start	End
ENSE00001288090	154818492	154820472
ENSE00002118912	154850483	154850603
ENSE00003475394	154830801	154830922
ENSE00003481760	154823387	154823592
ENSE00003488248	154822472	154822577
ENSE00003542229	154821260	154821426
ENSE00003544283	154834625	154834728
ENSE00003570952	154838131	154838178
ENSE00003626286	154834843	154834934

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 97.47.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.0751 / max 1166.5627, expressed in 1347 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
64472	10.3791	1148
64467	2.0507	160
64468	1.8686	220
64466	0.9417	136
64473	0.6766	347
64469	0.4990	192
64465	0.2370	47
64474	0.1948	66
64464	0.1685	55
64471	0.0474	22

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	97.47	gold quality
ileal mucosa	UBERON:0000331	97.44	gold quality
tibialis anterior	UBERON:0001385	96.97	silver quality
corpus callosum	UBERON:0002336	96.75	gold quality
right coronary artery	UBERON:0001625	96.70	gold quality
subthalamic nucleus	UBERON:0001906	96.61	gold quality
right lung	UBERON:0002167	96.45	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.44	gold quality
spinal cord	UBERON:0002240	96.35	gold quality
saphenous vein	UBERON:0007318	96.08	gold quality
mucosa of stomach	UBERON:0001199	96.03	gold quality
ventral tegmental area	UBERON:0002691	95.49	gold quality
trigeminal ganglion	UBERON:0001675	95.37	gold quality
calcaneal tendon	UBERON:0003701	95.17	gold quality
lateral globus pallidus	UBERON:0002476	95.11	gold quality
dorsal plus ventral thalamus	UBERON:0001897	95.05	gold quality
monocyte	CL:0000576	95.00	gold quality
mononuclear cell	CL:0000842	94.97	gold quality
coronary artery	UBERON:0001621	94.97	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.80	gold quality
left coronary artery	UBERON:0001626	94.77	gold quality
medulla oblongata	UBERON:0001896	94.60	gold quality
synovial joint	UBERON:0002217	94.49	gold quality
tibial nerve	UBERON:0001323	94.45	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.31	gold quality
dorsal root ganglion	UBERON:0000044	94.28	gold quality
superior vestibular nucleus	UBERON:0007227	94.26	gold quality
liver	UBERON:0002107	94.06	gold quality
urethra	UBERON:0000057	94.05	gold quality
midbrain	UBERON:0001891	94.03	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-75367	yes	405.19
E-GEOD-99795	yes	350.20
E-CURD-112	yes	43.15
E-MTAB-10042	yes	23.75
E-MTAB-5061	no	3.49
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting FAXDC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-4688	99.48	64.68	828
HSA-MIR-6743-5P	99.48	63.60	721
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-3922-3P	99.25	64.96	1136
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-6768-3P	99.14	67.38	1319

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	faxdc2	ENSDARG00000023820
mus_musculus	Faxdc2	ENSMUSG00000086962
rattus_norvegicus	Faxdc2	ENSRNOG00000027259
drosophila_melanogaster	CG1998	FBGN0030485
drosophila_melanogaster	CG11162	FBGN0030509
caenorhabditis_elegans		WBGENE00009902
caenorhabditis_elegans		WBGENE00009903

Paralogs (3): MSMO1 (ENSG00000052802), SC5D (ENSG00000109929), CH25H (ENSG00000138135)

Protein

Protein identifiers

Fatty acid hydroxylase domain-containing protein 2 — Q96IV6 (reviewed: Q96IV6)

All UniProt accessions (9): Q96IV6, E5RFJ7, E5RH66, E5RH84, E5RIK6, E5RJN8, E5RJQ9, E5RK01, E5RK16

UniProt curated annotations — full annotation on UniProt →

Function. Promotes megakaryocyte differentiation by enhancing ERK phosphorylation and up-regulating RUNX1 expression.

Subcellular location. Cytoplasm. Membrane.

Tissue specificity. Down-regulated in primary acute myeloid leukemia (AML) patients.

Induction. Up-regulated during 12-O-tetradecanoyl phorbol-acetate (TPA)-induced megakaryocytic differentiation of K562 cells.

Similarity. Belongs to the sterol desaturase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96IV6-1	1	yes
Q96IV6-2	2

RefSeq proteins (1): NP_115761* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006694	Fatty_acid_hydroxylase	Domain
IPR050307	Sterol_desaturase-rel	Family

Pfam: PF04116

UniProt features (10 total): transmembrane region 6, chain 1, domain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96IV6-F1	92.28	0.79

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 125 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_PHOSPHORYLATION, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, GOZGIT_ESR1_TARGETS_DN, GOBP_REGULATION_OF_HEMOPOIESIS, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, GOBP_REGULATION_OF_MEGAKARYOCYTE_DIFFERENTIATION, DELYS_THYROID_CANCER_DN, GOBP_STEROID_BIOSYNTHETIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_MYELOID_CELL_DIFFERENTIATION

GO Biological Process (4): positive regulation of protein phosphorylation (GO:0001934), sterol biosynthetic process (GO:0016126), positive regulation of megakaryocyte differentiation (GO:0045654), lipid biosynthetic process (GO:0008610)

GO Molecular Function (4): C-4 methylsterol oxidase activity (GO:0000254), iron ion binding (GO:0005506), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (3): cytoplasm (GO:0005737), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
regulation of protein phosphorylation	1
protein phosphorylation	1
positive regulation of protein modification process	1
positive regulation of phosphorylation	1
steroid biosynthetic process	1
sterol metabolic process	1
megakaryocyte differentiation	1
positive regulation of myeloid cell differentiation	1
regulation of megakaryocyte differentiation	1
lipid metabolic process	1
biosynthetic process	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, another compound as one donor, and incorporation of one atom of oxygen	1
transition metal ion binding	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1

Protein interactions and networks

STRING

1268 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAXDC2	ZNF134	P52741	576
FAXDC2	ZNF160	Q9HCG1	526
FAXDC2	FA2H	Q7L5A8	518
FAXDC2	EFTUD2	Q15029	505
FAXDC2	TM7SF2	O76062	459
FAXDC2	STYX	Q8WUJ0	450
FAXDC2	KRTAP19-5	Q3LI72	447
FAXDC2	A0A0J9YXS1	A0A0J9YXS1	428
FAXDC2	RETSAT	Q6NUM9	419
FAXDC2	COPZ1	P61923	419
FAXDC2	FDFT1	P37268	414
FAXDC2	CYP51A1	Q16850	413
FAXDC2	H1-10	Q92522	408
FAXDC2	SLC14A1	Q13336	400
FAXDC2	TP53	P04637	388

IntAct

97 interactions, top by confidence:

A	B	Type	Score
FAXDC2		psi-mi:“MI:0915”(physical association)	0.560
FAXDC2	TMX2	psi-mi:“MI:0915”(physical association)	0.560
STX4	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
CREB3L1	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
FAXDC2	TMEM106C	psi-mi:“MI:0915”(physical association)	0.560
TMPRSS2	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
RETREG3	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
ARL13B	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
FAXDC2	CGRRF1	psi-mi:“MI:0915”(physical association)	0.560
FAXDC2	ELOVL4	psi-mi:“MI:0915”(physical association)	0.560
GOLT1A	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
SLC10A1	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
CYB5R3	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
CD79A	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
NEMP1	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
FFAR2	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
PGRMC2	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
FAXDC2	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
GPR152	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
FAXDC2	PANX1	psi-mi:“MI:0915”(physical association)	0.560
EBP	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
SLC10A6	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
GPX8	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
TMEM139	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560
CLDN7	FAXDC2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (36): FAXDC2 (Two-hybrid), FAXDC2 (Affinity Capture-RNA), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid), FAXDC2 (Two-hybrid)

ESM2 similar proteins: A0JPQ8, A8MWK0, A9SIZ6, B6JWP7, C4QVU3, C4R613, D6WJ77, F1Q8R9, G5ECD6, I1MSF2, O13846, O17554, O31250, O74787, O94298, O94673, P21147, P25338, P68434, P9WNZ8, P9WNZ9, Q03529, Q296J9, Q2LAM0, Q2U0S9, Q4R4P4, Q567X1, Q5GKZ7, Q5M8F9, Q5MPP0, Q5R7H4, Q6GNM0, Q6NYE4, Q6RS96, Q6ZNB7, Q754G0, Q7L5A8, Q8BS35, Q8NKG9, Q8WZK2

Diamond homologs: A0A0D1DT68, B8B6I2, I1RFM2, I1S1Q3, O35532, O75845, P50860, P53045, Q15800, Q4R4Q4, Q4W9I3, Q4WDL3, Q4WIX5, Q55D54, Q5R574, Q5ZLL6, Q69L93, Q6UGB2, Q754B9, Q7SBB6, Q7ZW77, Q8J207, Q96IV6, Q9CRA4, Q9GKT2, A0A0E0SNE8, O13666, O88822, O93875, O94457, P32353, Q39208, Q4WB51, Q59VG6, Q8NJ57, Q9AST3, Q9EQS5, Q9M883, Q9UUH4, Q9ZT29

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1625 predictions. Top by Δscore:

Variant	Effect	Δscore
5:154820471:ACCTA:A	acceptor_loss	1.0000
5:154820472:CCT:C	acceptor_loss	1.0000
5:154820473:C:CC	acceptor_gain	1.0000
5:154820474:T:C	acceptor_loss	1.0000
5:154822470:A:AC	donor_gain	1.0000
5:154822470:ACTG:A	donor_gain	1.0000
5:154822471:C:CC	donor_gain	1.0000
5:154822471:CTG:C	donor_gain	1.0000
5:154822471:CTGC:C	donor_gain	1.0000
5:154823411:T:TA	donor_gain	1.0000
5:154830799:A:AC	donor_gain	1.0000
5:154830800:C:CC	donor_gain	1.0000
5:154834730:T:C	acceptor_gain	1.0000
5:154821254:CCTT:C	donor_loss	0.9900
5:154821255:CTT:C	donor_loss	0.9900
5:154821256:TTA:T	donor_loss	0.9900
5:154821257:TA:T	donor_loss	0.9900
5:154821258:A:AC	donor_gain	0.9900
5:154821258:A:C	donor_loss	0.9900
5:154821259:C:CC	donor_gain	0.9900
5:154823381:GCTCA:G	donor_loss	0.9900
5:154823382:CTCAC:C	donor_loss	0.9900
5:154823383:T:TC	donor_loss	0.9900
5:154823384:CAC:C	donor_loss	0.9900
5:154823385:A:AC	donor_gain	0.9900
5:154823385:A:AT	donor_loss	0.9900
5:154823386:C:CC	donor_gain	0.9900
5:154823386:C:CT	donor_loss	0.9900
5:154823412:C:A	donor_gain	0.9900
5:154823521:C:CT	acceptor_gain	0.9900

AlphaMissense

2203 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:154822525:A:G	W209R	0.992
5:154822525:A:T	W209R	0.992
5:154821267:G:C	H280D	0.991
5:154821265:A:C	H280Q	0.989
5:154821265:A:T	H280Q	0.989
5:154821270:G:C	H279D	0.989
5:154823387:C:G	R191P	0.985
5:154820409:G:C	F303L	0.984
5:154820409:G:T	F303L	0.984
5:154820411:A:G	F303L	0.984
5:154822534:G:C	H206D	0.984
5:154821267:G:T	H280N	0.983
5:154821319:G:C	H262Q	0.983
5:154821319:G:T	H262Q	0.983
5:154820437:T:A	D294V	0.981
5:154820438:C:G	D294H	0.980
5:154822509:C:T	G214D	0.980
5:154820469:G:C	F283L	0.979
5:154820469:G:T	F283L	0.979
5:154820471:A:G	F283L	0.979
5:154821270:G:T	H279N	0.979
5:154821312:A:C	Y265D	0.979
5:154821357:A:G	W250R	0.979
5:154821357:A:T	W250R	0.979
5:154822523:C:A	W209C	0.979
5:154822523:C:G	W209C	0.979
5:154820410:A:G	F303S	0.978
5:154820437:T:G	D294A	0.978
5:154821318:A:G	C263R	0.978
5:154822510:C:G	G214R	0.978

dbSNP variants (sampled 300 via entrez): RS1000156060 (5:154833934 C>T), RS1000207924 (5:154842447 A>C,G), RS1000207946 (5:154833627 T>G), RS1000235983 (5:154845140 C>A), RS1000288502 (5:154844829 G>C), RS1000338086 (5:154827103 G>A), RS1000409633 (5:154833911 A>C), RS1000426676 (5:154852332 G>A), RS1000439603 (5:154851892 CAAAAT>C), RS1000510983 (5:154832200 G>A), RS1000604341 (5:154831837 C>T), RS1000621043 (5:154846669 G>A), RS1000643150 (5:154839199 GCCTGTTGTC>G), RS1000786736 (5:154824847 G>C), RS1000836031 (5:154826841 C>T)

Disease associations

OMIM: gene MIM:619853 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (2): autism (MONDO:0005260), schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003043_99	Inflammatory bowel disease	2.000000e-07
GCST003045_44	Ulcerative colitis	2.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	9
sodium arsenite	decreases expression, increases abundance	3
Nickel	decreases expression, increases expression	3
Cyclosporine	decreases expression	3
bisphenol A	increases expression, affects cotreatment	2
Acetaminophen	decreases expression, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Cisplatin	affects expression, affects cotreatment, increases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Silicon Dioxide	decreases expression	2
Aflatoxin B1	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
9,10-dihydro-9,10-dihydroxybenzo(a)pyrene	decreases expression	1
lei gong teng	increases expression	1
epigallocatechin gallate	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
incobotulinumtoxinA	increases expression	1
Decitabine	affects expression	1
Sunitinib	decreases expression	1
Leflunomide	increases expression	1
Air Pollutants, Occupational	increases expression	1
Ethanol	affects cotreatment, increases expression	1
Arsenic	decreases expression, increases abundance	1

Clinical trials (associated diseases)

599 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety